Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

UK trial starts for BPH (benign prostatic hyperplasia) ethanol injection therapy:

This article was originally published in Clinica

Executive Summary

UK researchers have begun a trial to assess American Medical Systems' (AMS) ProstaJect minimally invasive ethanol injection system for treating benign prostatic hyperplasia. Some 20 patients will be treated in the study led by Mr John Palmer of the Medway Maritime Hospital in Kent. Minneapolis, Minnesota-based AMS is also expanding the trial to include 250 patients in six additional European countries over the next six months. The company said that the ProstaJect procedure can be performed in as little as 20 minutes under a local anaesthetic.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT076876

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel